Core Insights - The report highlights that the total salary of A-share listed company secretaries reached 4.086 billion yuan in 2024, with an average annual salary of 754,300 yuan [1] - Over 21% of the secretaries earn more than 1 million yuan annually, indicating a significant compensation level in the industry [1] Salary Distribution - The salary distribution among secretaries in the biopharmaceutical sector shows that 32% earn below 500,000 yuan, 41% earn between 500,000 and 1 million yuan, 23% earn between 1 million and 2 million yuan, 3% earn between 2 million and 3 million yuan, and 1% earn above 3 million yuan [5] - Five secretaries with salaries exceeding 3 million yuan include Li Wenmei from Mindray Medical (7.3876 million yuan), Jiang Yueheng from Yifang Bio (5.2065 million yuan), and others, with the youngest being 32 years old [7] Age and Educational Background - The age distribution of secretaries shows that those aged 40-50 constitute 47%, while those over 50 account for 23%, and those aged 30-40 make up 29%. Secretaries under 30 represent 1% [1] - In terms of educational qualifications, 4% have an associate degree, 42% hold a bachelor's degree, 50% possess a master's degree, and 4% have a doctoral degree, with over half holding a master's degree or higher [3] Investor Engagement - There is a significant variance in the number of investor meetings held by companies, with 32% of companies hosting fewer than 10 meetings annually, while only 1% have more than 1,000 meetings [9] - The top five companies with the most investor meetings include Sanofi Biologics and others, with meeting counts ranging from 1,107 to 2,661 [10]

Core Insights - The report highlights that in 2024, the total salary of A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan annually, accounting for more than 21% of the total [1] Salary Distribution - The salary distribution for company secretaries in the A-share biopharmaceutical sector is as follows: - Below 500,000 yuan: 153 individuals (32%) - 500,000 to 1 million yuan: 199 individuals (41%) - 1 million to 2 million yuan: 114 individuals (23%) - 2 million to 3 million yuan: 16 individuals (3%) - Over 3 million yuan: 5 individuals (1%) [5] Age Distribution - The age distribution of company secretaries shows that: - Ages 40-50: 47% - Ages 50 and above: 23% - Ages 30-40: 29% - Under 30: 1%, with the youngest being 28 years old [1] Educational Background - The educational qualifications of company secretaries are as follows: - Associate degree: 4% - Bachelor's degree: 42% - Master's degree: 50% - Doctorate: 4% - More than half of the company secretaries hold a master's degree or higher [3] Investor Engagement - The frequency of investor engagements varies significantly among companies: - Less than 10 times: 129 companies (32%) - 10 to 100 times: 149 companies (37%) - 100 to 300 times: 79 companies (20%) - 300 to 1000 times: 42 companies (10%) - More than 1000 times: 5 companies (1%) [7] Top Investor Engagement Companies - The companies with the highest number of investor engagements are: - Sanofi Biologics: 2,661 times - Bohui Innovation: 1,500 times - Zexin Pharmaceutical: 1,418 times - Aibo Medical: 1,263 times - Kangtai Medical: 1,107 times [9]

Core Viewpoint - The report outlines the verification opinions of China International Capital Corporation regarding the lifting of restrictions on the circulation of part of the restricted shares of Shanghai Mengke Pharmaceutical Co., Ltd. The restricted shares will be available for trading on August 5, 2025, involving a total of 159,444,366 shares, which accounts for 24.32% of the company's total share capital [1][3][8]. Group 1: Restricted Shares Details - The total number of shares after the initial public offering (IPO) is 655,210,084, with 118,687,659 shares being unrestricted and 536,522,425 shares being restricted [2]. - The restricted shares involved in this circulation are from five shareholders, with a lock-up period of 36 months from the date of the company's stock listing [3]. - The total number of restricted shares to be listed for circulation is 159,444,366, which will be available for trading on August 5, 2025 [4][6]. Group 2: Share Capital Changes - Following the implementation of the 2023 restricted stock incentive plan, the company's total share capital increased from 655,210,084 shares to 655,605,491 shares [3]. - The increase in share capital is attributed to the vesting of restricted stocks under the incentive plan [3]. Group 3: Shareholder Commitments - Shareholders have made commitments regarding the locked shares, including not transferring or proposing to repurchase the shares during the lock-up period of 36 months [5][6]. - After the lock-up period, shareholders plan to reduce their holdings in compliance with relevant laws and regulations, ensuring that the selling price will not be lower than the IPO price adjusted for any corporate actions [5][6]. Group 4: Verification Opinions - The sponsor institution, China International Capital Corporation, has verified that the application for the lifting of restrictions on the shares complies with relevant laws and regulations, and the shareholders have adhered to their commitments made during the IPO [7][8].

Core Viewpoint - Shanghai Mengke Pharmaceutical Co., Ltd. is set to list 159,444,366 restricted shares for trading on August 5, 2025, following its initial public offering (IPO) [1][3][6] Group 1: Listing Details - The total number of shares for this listing is 159,444,366, which are part of the restricted shares from the company's IPO [1][6] - The shares will be available for trading starting on August 5, 2025 [1][6] - The company received approval from the China Securities Regulatory Commission for the public offering of 13 million shares, which were listed on August 5, 2022 [1][3] Group 2: Shareholder Information - The restricted shares involve five shareholders: MicuRx(HK) Limited, Best Idea International Limited, JSR Limited, GP TMT Holdings Limited, and Xinyi Youmaikos Financial Consulting Center (Limited Partnership) [3][6] - The restricted period for these shares is 36 months from the date of the company's stock listing [3][4] Group 3: Changes in Share Capital - Following the implementation of the 2023 restricted stock incentive plan, the company's total share capital increased from 655,210,084 shares to 655,605,491 shares [2][3] - The increase in share capital is attributed to the vesting of restricted stocks under the incentive plan [2][3] Group 4: Shareholder Commitments - Shareholders have committed not to transfer or propose the repurchase of their shares during the 36-month lock-up period [4][5] - After the lock-up period, any share reduction must comply with relevant laws and regulations, ensuring that the selling price does not fall below the IPO price adjusted for any corporate actions [4][5] Group 5: Verification by Intermediaries - The sponsoring institution has verified that the application for the listing of restricted shares complies with legal requirements and that shareholders have adhered to their commitments [6]

证券代码：688373 证券简称：盟科药业 公告编号：2025-026 上海盟科药业股份有限公司 首次公开发行部分限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为首发限售股份；股票认购方式为网下，上市股数为 159,444,366股。 本次股票上市流通总数为159,444,366股。 本次股票上市流通日期为2025 年 8 月 5 日。 一、本次上市流通的限售股类型 本次上市流通的限售股属于公司首次公开发行部分限售股，共涉及限售股股 东5名（MicuRx(HK) Limited、Best Idea International Limited、JSR Limited、GP TMT Holdings Limited、新沂优迈科斯财务咨询中心（有限合伙）），限售期为自公司 股票上市之日起36个月，共涉及公司159,444,366股股份，占公司总股本比例为 24.32%。 本次上市流通的限售股将于2025年8月5日起上市流通。 二、本次上市流通的限售股形成后至今公司股本数量变化 ...

首次公开发行部分限售股解禁上市流通的核查意见 公司上市以来，因实施 2023 年限制性股票激励计划，根据《上海盟科药业股份有 限公司关于 2023 年限制性股票激励计划首次授予部分第一个归属期归属结果暨股份上 市公告》，相关限制性股票归属后，公司股本总数由 655,210,084 股增加至 655,605,491 股，具体情况如下： 中国国际金融股份有限公司关于上海盟科药业股份有限公司 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为上海 盟科药业股份有限公司（以下简称"盟科药业"或"公司"）首次公开发行股票并在 科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交易所 科创板股票上市规则（2025 年 4 月修订）》和《上海证券交易所科创板上市公司自律 监管指引第 1 号——规范运作（2025 年 5 月修订）》等有关规定，对盟科药业首次公 开发行部分限售股解禁上市流通事项进行了审慎核查，核查情况及核查意见如下： 一、本次上市流通的限售股类型 根据中国证券监督管理委员会出具的《关于同意上海盟科药业股份有限公司首次 公开发行股票注册的批复》（证监许可〔2022〕1204 号 ...

Investment Rating - The report assigns an "Accumulate" rating for the company, marking the first coverage [2][10]. Core Insights - The report highlights the focus on innovative antibacterial treatments, particularly the commercialization of the core product, Contizole, and the ongoing development of its pipeline products [8][9][11]. - The company is positioned in the growing market of antibiotic resistance, with a strong emphasis on addressing clinical challenges through differentiated innovation [13][20]. Financial Forecast and Valuation - Projected revenues for the company from 2025 to 2027 are estimated at 1.74 billion, 2.05 billion, and 2.49 billion CNY respectively, reflecting a growth trajectory despite initial cash flow delays typical of biotech firms [10][46]. - The report utilizes a DCF valuation method, indicating that the current market valuation is relatively undervalued based on the company's growth potential and market position [10][21]. Business Overview - The company has established a solid domestic business foundation, with its core product, Contizole, showing significant sales growth of 88.3% in 2023 and projected continued growth of 43.51% in 2024 [4][27]. - The company has expanded its hospital coverage to 582 hospitals, with 150 hospitals formally approved for bulk procurement, enhancing market penetration [4][27]. Pipeline Development - The report details the ongoing global Phase III clinical trials for MRX-4, which is aimed at treating diabetic foot infections, and highlights the successful completion of Phase I trials for MRX-5 and MRX-8 [7][41][43]. - The company is actively pursuing international clinical development for its innovative products, with MRX-5 receiving FDA orphan drug designation, indicating strong potential for market entry [7][41][43]. Competitive Positioning - The company is strategically positioned in the antibacterial sector, focusing on multi-drug resistant bacteria, and has developed a comprehensive product matrix to address various infection types [20][21]. - The innovative approach includes a dual coverage strategy for Gram-positive and Gram-negative bacteria, enhancing its competitive edge in the market [9][20].

FANGDA PARTNERS http://www.fangdalaw.com 中国上海市石门一路 288 号 电子邮件 E-mail: email@fangdalaw.com 兴业太古汇香港兴业中心二座 24 楼 电 话 Tel.: 86- 21-2208-1166 邮政编码：200041 传 真 Fax: 86-21-5298- 5599 HKRI Taikoo Hui Shanghai 200041, PRC 上海市方达律师事务所 关于上海盟科药业股份有限公司 致：上海盟科药业股份有限公司 上海市方达律师事务所（以下简称"本所"）是具有中华人民共和国境内法律 执业资格的律师事务所。根据相关法律顾问协议，本所指派律师出席上海盟科药 业股份有限公司（以下简称"公司"）2025 年第一次临时股东大会（以下简称"本 次股东大会"），并就本次股东大会的召集和召开程序、参与表决和召集会议人员 的资格、表决程序和表决结果等有关事宜出具本法律意见书。 本法律意见书依据《中华人民共和国公司法》 《中华人民共和国证券法》 《上 市公司股东会规则》及其他相关中华人民共和国境内已公开颁布并生效的法律、 法规、规章及规范性文件 ...

律师：王俞淞、张超 本次股东大会的召集、召开程序符合有关中国法律法规和《公司章程》的规 定；参与本次股东大会表决的人员资格合法、有效；本次股东大会召集人的资格 合法、有效；本次股东大会的表决程序和表决结果合法、有效。 特此公告。 上海盟科药业股份有限公司董事会 | 证券代码：688373 证券简称：盟科药业 | 公告编号：2025-025 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 上海盟科药业股份有限公司 | | | | | | | | 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 | | | | | | | | 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | | | | | | | | 重要内容提示： | | | | | | | | ? 本次会议是否有被否决议案：无 | | | | | | | | 一、 会议召开和出席情况 | | | | | | | | （一） 股东大会召开的时间：2025 年 | 17 日 | | 7 月 | | | | | （二） | 股东大会召开的地点：中国（上海）自 ...

FANGDA PARTNERS http://www.fangdalaw.com 中国上海市石门一路 288 号 电子邮件 E-mail: email@fangdalaw.com 兴业太古汇香港兴业中心二座 24 楼 电 话 Tel.: 86-21-2208-1166 邮政编码：200041 传 真 Fax: 86-21-5298-5599 24/F, HKRI Centre Two HKRI Taikoo Hui 288 Shi Men Yi Road Shanghai 200041, PRC 上海市方达律师事务所 关于上海盟科药业股份有限公司 2025 年第一次临时股东大会的法律意见书 致：上海盟科药业股份有限公司 上海市方达律师事务所（以下简称"本所"）是具有中华人民共和国境内法律 执业资格的律师事务所。根据相关法律顾问协议，本所指派律师出席上海盟科药 业股份有限公司（以下简称"公司"）2025 年第一次临时股东大会（以下简称"本 次股东大会"），并就本次股东大会的召集和召开程序、参与表决和召集会议人员 的资格、表决程序和表决结果等有关事宜出具本法律意见书。 根据公司于 2025 年 7 月 2 日公告 ...